• See Section 6 regarding identifying patients at moderate risk of hospitalization.
• The GDG considered that nirmatrelvir-ritonavir represents a superior choice to molnupiravir because it probably has a greater reduction in hospitalization and because of concerns about possible harms of molnupiravir.
• In moderate risk patients for whom nirmatrelvir-ritonavir is not an option where a choice exists between molnupiravir and remdesivir, key considerations will be the potential toxicity of molnupiravir, its possible reduction in duration of symptoms, and the burden of remdesivir in requiring 3 days of intravenous injections.

Practical info Given the conditional recommendation against using molnupiravir for patients with non-severe COVID-19 at moderate risk of hospitalizations, practical considerations were felt to be less relevant here. See practical info for use of molnupiravir in patients with COVID-19 at high risk of hospitalization if needed.